As shown in Figure 1(b), the percentage of CD4+Foxp3+ Treg cells from PBMCs increased in NSCLC patients compared to healthy donors (1.76 ± 0.17% versus 1.01 ± 0.16%, P < 0.01). This evidence concerns the gene FOXP3 and non-small cell lung carcinoma.